UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
100% efficacy against severe Covid-19 disease and hospitalizations
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Methodology developed by QIMR Berghofer researchers utilizing the Agilent Cary 630 FTIR
The new wing will cater to all aspects of mother and child health by offering comprehensive, end to end services in radiology, diagnostics, obstetric surgeries and an exclusive gynaecology emergency section
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern
Subscribe To Our Newsletter & Stay Updated
